Tyr221
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.0.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr221  -  SOCS3 (human)

Site Information
IREFLDQyDAPL___   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 450447

In vivo Characterization
Methods used to characterize site in vivo:
mutation of modification site ( 1 , 2 , 3 ) , phospho-antibody ( 1 , 2 , 3 ) , western blotting ( 1 , 2 , 3 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
JAK2 (human) ( 3 )
Kinases, in vitro:
Lck (human) ( 3 )
Treatments:
cycloheximide ( 3 ) , EGF ( 3 ) , LPS ( 3 ) , PDGF ( 2 ) , vanadate ( 3 )

Downstream Regulation
Effects of modification on SOCS3:
molecular association, regulation ( 2 , 3 ) , protein degradation ( 1 , 3 )
Effects of modification on biological processes:
transcription, altered ( 1 )
Induce interaction with:
CRK (human) ( 2 ) , NCK1 (human) ( 2 )
Inhibit interaction with:
TCEB1 (human) ( 3 )

References 

1

Qasimi P, et al. (2006) Divergent mechanisms utilized by SOCS3 to mediate interleukin-10 inhibition of tumor necrosis factor alpha and nitric oxide production by macrophages. J Biol Chem 281, 6316-24
16352613   Curated Info

2

Sitko JC, Guevara CI, Cacalano NA (2004) Tyrosine-phosphorylated SOCS3 interacts with the Nck and Crk-L adapter proteins and regulates Nck activation. J Biol Chem 279, 37662-9
15173187   Curated Info

3

Haan S, et al. (2003) Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation. J Biol Chem 278, 31972-9
12783885   Curated Info